Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its LUCID-MS program, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis (MS). The company announced the completion of Phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. This milestone is significant given the urgent need for therapies that can protect or restore myelin integrity, which is crucial for addressing loss of mobility and bodily function in MS patients.
Multiple sclerosis affects more than 2.8 million people worldwide and approximately 1 million in the USA. Despite available immune-modulating treatments, many patients experience worsening disability because current therapies focus on reducing inflammation and relapse frequency but may not adequately address underlying neurodegeneration and myelin damage. Quantum BioPharma’s LUCID-MS aims to fill this gap by directly targeting the myelin sheath, the protective covering of nerve fibers that is attacked by the immune system in MS.
The company reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS. This regulatory step paves the way for further clinical development. According to the press release, the therapy is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
For more information on Quantum BioPharma and its latest news, visit the company’s newsroom at https://ibn.fm/QNTM. BioMedWire, which disseminated this announcement, is a specialized communications platform focusing on biotechnology and life sciences sectors. It is part of the Dynamic Brand Portfolio @IBN, offering services including press release enhancement and social media distribution. For more details, visit https://www.BioMedWire.com.
The progression of LUCID-MS represents a potential paradigm shift in MS treatment, moving beyond symptom management toward addressing the root cause of disability. If successful in later-stage trials, it could offer new hope to millions of patients worldwide who currently face progressive neurological decline.
